Adherence to immunosuppressive therapy after kidney transplantation is crucial to avoid graft rejection and optimise long term patient and graft survival. However, patient's adherence is not always optimal. Our aim was to identify reasons for non-adherence and health-related quality of life (HRQoL) dimensions affected by immunosuppressant therapy (IT) after kidney transplantation (KT) including patient preference of once daily over twice daily immunosuppressive regimen. MethOds: A literature review on adherence to immunosuppressant therapy (IT) and impact of IT on HRQoL through the EMBASE database was performed. Interviews were conducted with 2 clinical experts to determine key concepts related to KT and immunosuppressants. Thirty-six patients in four focus groups were asked to cite important concepts related to adherence and impact of IT on HRQoL and rate them. Qualitative analysis was conducted to code patient's responses. Results: The results showed that non-adherence was mostly unintentional among the participants. The reason for non-adherence included forgetfulness, interference with lifestyle, being asleep at the time the medication should be taken, change in routine and impact of side effects. The twice daily regimen was more problematic in relation to adherence. Overall, participants were of the opinion that a once daily IT regimen would help them be more adherent. Also, IT impacts on the HRQoL of the patient in a number of ways including: restricting the patients' lifestyle, causing anxiety or impairing the patient's ability to work. Although the patients happily oblige to the necessity of taking IT medication, patients preferred to reduce the burden associated with medication. cOnclusiOns: This study suggested that patients strongly valued adherence to IT medication and saw a change in the regimen from twice daily to once daily as one way to improve their adherence to IT. Results also suggested that a once daily regimen could improve patient's HRQoL.
Introducción El priapismo se define como una erección parcial o completa que dura más de 4 horas en ausencia de estímulo sexual. Se clasifica en isquémico, no isquémico e intermitente. El primero corresponde a la mayoría de casos y puede producirse por un estímulo sexual o por medicamentos. El manejo inicial consiste en la aspiración de los cuerpos cavernosos y la inyección de simpaticomiméticos. Cuando esas medidas fallan, el manejo quirúrgico está indicado. Entre las complicaciones más frecuentes está la disfunción eréctil, sin embargo, en la literatura, hay muy pocos reportes de necrosis de pene. Descripción del Caso Clínico Paciente de 60 años de edad que presentó priapismo isquémico luego de la inyección intracavernosa de prostaglandina E. Viene a consulta y le realizan lavado de cuerpos cavernosos con inyección de simpaticomiméticos que no fue exitoso; por lo que le realizan fístula espongio-cavernosa distal (Al-Ghorab) y rafia de uretra por lesión advertida. Consulta nuevamente por persistencia de edema, áreas necróticas y sangrado en glande. Se decidió iniciar manejo médico. Presentó evolución estacionaria y aumento en necrosis por lo que se derivó con cistostomía y se realizó desbridamiento de tejido necrótico inicialmente. Posteriormente se realizó Reconstrucción peneana + Uretroplastia peneana + Lavado desbridamiento de tejidos + Cistoscopia con buena evolución clínica. Conclusiones Existen diferentes factores de riesgo para presentar priapismo de origen isquémico como es la inyección de medicamentos intracavernosos. La principal complicación que se presenta es la disfunción eréctil. Sin embargo, hay pocos casos descritos de necrosis de glande. En el caso de nuestro paciente se plantean diferentes hipótesis como factores contribuyentes a la necrosis como son el uso de simpaticomiméticos y/o la desvascularización del glande posterior a la cirugía. Al enfocar ese tipo de paciente, es indispensable realizar un adecuado manejo inicial para prevenir ese tipo de complicación que, aunque es poco frecuente, puede resultar catastrófica.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.